How do you use Exparel in a sentence? See 3 example sentences showing how this word appears in different contexts.
Exparel in a sentence
Context around Exparel
- Average sentence length in these examples: 18.7 words
- Position in the sentence: 1 start, 1 middle, 1 end
- Sentence types: 3 statements, 0 questions, 0 exclamations
Corpus analysis for Exparel
- In this selection, "exparel" usually appears near the start of the sentence. The average example has 18.7 words, and this corpus slice is mostly made up of statements.
- Around the word, drug, painkiller and citing stand out and add context to how "exparel" is used.
- Recognizable usage signals include s painkiller exparel at risk and the drug exparel is marketed. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "exparel" sits close to words such as aaaaand, aaah and aacl, which helps place it inside the broader word index.
Example types with exparel
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
The drug, Exparel, is marketed as an alternative to opioid painkillers post-surgery. (13 words)
Janney analyst Ken Trbovich argued that puts Pacira's painkiller, Exparel, at risk. (13 words)
Nurses received a memo this summer that the medical center was restricting its use of Exparel, citing a lack of published research to justify broad use of the injectable anesthetic. (30 words)
Nurses received a memo this summer that the medical center was restricting its use of Exparel, citing a lack of published research to justify broad use of the injectable anesthetic. (30 words)
The drug, Exparel, is marketed as an alternative to opioid painkillers post-surgery. (13 words)
Janney analyst Ken Trbovich argued that puts Pacira's painkiller, Exparel, at risk. (13 words)
Example sentences (3)
Nurses received a memo this summer that the medical center was restricting its use of Exparel, citing a lack of published research to justify broad use of the injectable anesthetic.
The drug, Exparel, is marketed as an alternative to opioid painkillers post-surgery.
Janney analyst Ken Trbovich argued that puts Pacira's painkiller, Exparel, at risk.